Moderna Inc
MRNA24.770USD
-0.190-0.76%
收盤 11/14, 16:00（美東）報價延遲15分鐘
9.69B總市值
虧損本益比TTM
關於 Moderna Inc 公司
Moderna, Inc. 是一家生物技術公司。該公司正在開發一種由信使核糖核酸 (mRNA) 製成的新藥。該公司正在獨立或與戰略合作伙伴一起開發用於傳染病、免疫腫瘤學、罕見疾病和自身免疫性疾病的療法和疫苗。mRNA 藥物旨在引導人體細胞產生具有治療或預防益處的細胞內、膜或分泌蛋白，並有可能治療一系列疾病。其多樣化的開發渠道包括 45 個治療和疫苗項目，其中 9 個處於後期開發階段。其產品包括 COVID-19 疫苗（mRNA-1273/Spikevax、下一代 mRNA-1283）、RSV 疫苗（mRNA-1345）、季節性流感疫苗（mRNA-1010、mRNA-1011、mRNA-1012、mRNA-1020 和 mRNA-1030）、聯合疫苗（mRNA-1083、mRNA-1230、mRNA-1045 和 mRNA-1365）、CMV 疫苗（mRNA-1647）、EBV 疫苗（mRNA-1189 和 mRNA-1195）等。
Moderna Inc簡介
公司代碼MRNA
公司名稱Moderna Inc
上市日期Dec 07, 2018
CEOMr. Stephane Bancel
員工數量5800
證券類型Ordinary Share
年結日Dec 07
公司地址325 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話16177146500
網址https://www.modernatx.com/
公司代碼MRNA
上市日期Dec 07, 2018
CEOMr. Stephane Bancel
Moderna Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
28.17K
+2.16%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
18.26K
+4.28%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
28.17K
+2.16%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
18.26K
+4.28%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
業務USD
名稱
營收
佔比
COVID
114.00M
0.00%
RSV
0.00
0.00%
地區USD
名稱
營收
佔比
United States
88.00M
77.19%
Rest of the World
26.00M
22.81%
Europe
0.00
0.00%
業務
地區
業務USD
名稱
營收
佔比
COVID
114.00M
0.00%
RSV
0.00
0.00%
股東統計
更新時間: 23 小時前
更新時間: 23 小時前
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
其他
70.73%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
其他
70.73%
股東類型
持股股東
佔比
Investment Advisor
38.96%
Investment Advisor/Hedge Fund
14.16%
Hedge Fund
10.34%
Corporation
4.63%
Research Firm
4.51%
Individual Investor
2.54%
Bank and Trust
1.37%
Venture Capital
1.19%
Pension Fund
1.17%
其他
21.14%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
1925
289.85M
74.21%
-20.82M
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
41.62M
10.7%
+1.37M
+3.40%
Jun 30, 2025
Baillie Gifford & Co.
22.09M
5.68%
-2.85M
-11.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.64M
5.05%
+1.76M
+9.86%
Jun 30, 2025
State Street Investment Management (US)
17.27M
4.44%
-507.93K
-2.86%
Jun 30, 2025
Two Sigma Investments, LP
14.77M
3.8%
+6.51M
+78.82%
Jun 30, 2025
Fidelity Management & Research Company LLC
19.46M
5%
-1.37M
-6.56%
Jun 30, 2025
Geode Capital Management, L.L.C.
8.88M
2.28%
+1.42M
+19.05%
Jun 30, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.37%
+160.31K
+1.77%
Mar 05, 2025
Theleme Partners LLP
7.87M
2.02%
+626.42K
+8.65%
Jun 30, 2025
D. E. Shaw & Co., L.P.
7.46M
1.92%
+1.83M
+32.42%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
3.76%
Global X Genomics & Biotechnology ETF
3.46%
First Trust NYSE Arca Biotechnology Index Fund
2.38%
SPDR S&P Biotech ETF
2.2%
VanEck Biotech ETF
1.84%
Invesco S&P 500 Equal Weight Health Care ETF
1.75%
Langar Global HealthTech ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.57%
ROBO Global Healthcare Technology & Innovation ETF
1.55%
WisdomTree BioRevolution Fund
1.42%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比3.76%
Global X Genomics & Biotechnology ETF
佔比3.46%
First Trust NYSE Arca Biotechnology Index Fund
佔比2.38%
SPDR S&P Biotech ETF
佔比2.2%
VanEck Biotech ETF
佔比1.84%
Invesco S&P 500 Equal Weight Health Care ETF
佔比1.75%
Langar Global HealthTech ETF
佔比1.61%
Virtus LifeSci Biotech Products ETF
佔比1.57%
ROBO Global Healthcare Technology & Innovation ETF
佔比1.55%
WisdomTree BioRevolution Fund
佔比1.42%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
